▶주메뉴 바로가기
▶본문 바로가기
[THE INVESTOR] Celltrion Healthcare, an affiliate of Korea’s leading biosimilar maker Celltrion, said on Nov. 14 it will set up a sales unit in Europe to generate stable revenue from biosimilars. ...
[THE INVESTOR] Korean biotech firm Bridge Biotherapeutics said on Nov. 13 it plans to begin phase 2 study of BBT-401, first Pellino-1 inhibitor as a treatment for ulcerative colitis, next month fo...
[THE INVESTOR] OliX Pharmaceuticals said on Nov. 12 that its partner Hugel has received approval from Korea’s Ministry of Food and Drug Safety to begin phase 2a clinical study on its RNA interferen...
[THE INVESTOR] LG Chem said on Nov. 12 that it will expand its drug portfolio to immuno oncology by forging a partnership with US biotech Cue Biopharma. With the exclusive license deal, LG Chem wi...
[THE INVESTOR] Korea’s leading biosimilar manufacturer Celltrion said on Nov.9 its third-quarter net profit plunged 49 percent from a year earlier due to price cuts and reduced output. Net profi...
[THE INVESTOR] Democratic Party lawmaker Park Yong-jin revealed on Nov. 7 a handful of documents that were exchanged between Samsung BioLogics and the control tower of Samsung regarding the contract...
[THE INVESTOR] Samsung BioLogics said on Nov. 6 it is close to wrapping up an asset transfer deal with US-based Biogen to sell its shares in their joint venture Samsung Bioepis. Samsung BioLogics w...
[THE INVESTOR] Korea’s GC Pharma said on Nov. 5 that its US subsidiary Curevo has received approval from the US Food and Drug Administration to begin phase 1 clinical trials of CRV-101, its vaccine ...
[THE INVESTOR] Korean pharmaceutical company Yuhan said on Nov. 5 that it has signed a deal with Janssen Biotech to license out Lazertinib, a novel clinical-stage therapeutic candidate for the treat...
[THE INVESTOR] Celltrion Healthcare , the marketing arm of Celltrion, said on Nov. 2 that it has won big tenders for Herzuma, its biosimilar version of Roche’s blockbuster breast drug Herceptin in ...
[THE INVESTOR] Bukwang Pharmaceutical said on Oct. 31 US biotech Acer Therapeutics has submitted a New Drug Application with the US Food and Drug Administration for its drug candidate EDSIVO, a tre...
[THE INVESTOR] Korean pharmaceutical firm Samsung Bioepis has started research on a biosimilar for the drug Soliris, used to treat paroxysmal nocturnal hemoglobinuria, industry sources said on Oct. ...
[THE INVESTOR] Genexine and its US affiliate NeoImmuneTech said on Oct. 30 that the US Food and Drug Administration has approved its Investigational New Drug application for clinical trials of its ...
[THE INVESTOR] Hanmi Pharmaceuticals said on Oct. 30 that its partner Athenex will initiate clinical trials next year on an oncology drug candidate that has utilized its platform. The New York-bas...
[THE INVESTOR] SK Plasma said on Oct. 30 it has started operations at its new Andong plant, raising the company’s production capacity of plasma derivatives by nearly 500 percent. The 31,586-squa...
Netmarble stock price jumps as BTS hits another Billboard No. 1
MitoImmune Therapeutics secures funds worth W12b
AI startup 42Maru showcases solutions at AWS Summit Seoul 2019
Global tech firms face-off over foldable mobile displays
Greenpeace calls on Hyundai to hasten shift to carbon-neutrality
JYP chief becomes top stock-rich K-pop agency owner
S. Korea mobile carriers admit shaky 5G network in early stage
Nexon to host big gaming convention NDC 2019
April 23, 2019
